U.S. Physical Therapy, Inc. (USPH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed strong financial performance with increased revenues, margins, and EBITDA. The Q&A highlighted positive growth prospects, efficient cost management, and strategic acquisitions. Despite some concerns about wage inflation and unclear details on hospital rates, the company's optimistic guidance, improved margins, and strategic initiatives like AI-driven operations and acquisitions suggest a positive outlook. Given the company's market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Adjusted EBITDA Increased $13.2 million, a 16.2% improvement over the prior year period. This was achieved despite continued Medicare rate reductions in 2025.
Net Revenue Increased 16.3% year-over-year. Physical therapy revenue increased by 16%, and injury prevention business revenue increased by 18%.
Gross Profit (Physical Therapy Operations) Increased approximately 21% year-over-year, driven by demand, rate improvement, and cost discipline.
Gross Profit (Injury Prevention Business) Increased over 20% year-over-year, supported by strong demand and operational improvements.
Operating Income Improved 18.4% year-over-year, despite challenges such as Medicare rate reductions.
Average Visits Per Clinic Per Day (Q4 2025) Reached 32.7, the highest fourth-quarter volume in the company's history, marking 7 consecutive quarters of record-level visits.
Total Patient Visits Increased 11.2% year-over-year, supported by acquisitions and a 1.5% increase in visits at mature clinics.
Net Rate Per Patient Visit Increased 1% from $104.71 in 2024 to $105.76 in 2025, with Q4 2025 ending at $106.49, a 1.7% increase from Q4 2024.
Physical Therapy Revenues (Q4 2025) $173.8 million, an increase of $20 million or 13% from the previous year.
Physical Therapy Operating Costs (Q4 2025) $138.6 million, an increase of $12.9 million or 15.3% compared to the same quarter last year.
Salaries and Related Costs Per Visit (Q4 2025) Decreased by 1.1% from $62.85 in Q4 2024 to $62.15 in Q4 2025.
Total Operating Costs Per Visit (Q4 2025) Decreased 0.6% from just above $86 in Q4 2024 to $85.56 in Q4 2025.
Physical Therapy Adjusted Gross Margin (Q4 2025) 20.5%, up almost 200 basis points from 18.6% in Q4 2024.
IIP Net Revenues (Q4 2025) Increased $2.3 million or 8.7% compared to the same quarter last year.
IIP Income (Q4 2025) Increased $510,000 or 11.5%, with all growth being organic.
IIP Margin (Q4 2025) Increased from 16.7% in Q4 2024 to 17.1% in Q4 2025.
Adjusted EBITDA (Q4 2025) Increased $3 million from $21.8 million in Q4 2024 to $24.8 million in Q4 2025.
Operating Results (Q4 2025) $10.2 million, an increase of $2.5 million from $7.8 million in Q4 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Acquisitions: Several acquisitions were made, including one in the Pacific Northwest, a home care addition, and an injury prevention team. These acquisitions strengthen the company's presence in New York City and expand service offerings in the injury prevention segment.
Hospital Arrangements: Two significant long-term hospital arrangements were announced, expected to positively impact volume, margins, and growth opportunities. These will phase in for 70+ clinics by year-end 2026, contributing at least $14 million in EBITDA by 2027.
Market Expansion: Strengthened presence in New York City and expanded reach through strategic hospital affiliations, enhancing patient access and growth opportunities.
Operational Efficiencies: Implemented ambient listening documentation support, semi-virtualization of front desk operations, and expanded cash-based programs. Maintained cost discipline, reducing operating costs per visit by 0.6% in Q4 2025.
Visit Growth: Achieved record-high visits per clinic per day for seven consecutive quarters, with a 1.5% increase in visits at mature clinics.
Strategic Shifts: Focused on large market strategic hospital alliances and remote therapeutic monitoring, with plans for ongoing de novo and acquisition-related development in physical therapy and injury prevention segments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare rate reductions: Continued Medicare rate reductions in 2025 posed challenges to revenue and profitability, requiring the company to find ways to offset these impacts.
Cost management: Inflationary pressures required effective cost management to maintain operating margins, which could be a challenge in the future.
Hospital affiliation agreements: The hospital affiliation agreements, while promising, will require successful implementation and integration to achieve the expected financial benefits.
Enterprise-wide system implementation: The implementation of a new financial and human resources system by 2027 involves significant costs and operational risks during the transition period.
Competitive pressures: The company faces competitive pressures in both the physical therapy and injury prevention markets, necessitating continued innovation and strategic partnerships.
Regulatory changes: Changes implemented by CMS in 2026 for remote therapeutic monitoring could pose challenges in adapting operations to comply with new requirements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Hospital Affiliation Agreements: Two significant hospital affiliation agreements are expected to contribute at least $14 million to PT revenue and income, with a corresponding impact of at least $7.3 million to USPH's adjusted EBITDA by year-end 2026.
Adjusted EBITDA for 2026: Expected to be in the range of $102 million to $106 million, including $2.5 million in incremental revenue from the Medicare rate increase effective January 1, 2026.
Strategic Initiatives for 2026: Plans include the rollout of ambient listening documentation support, semi-virtualization of front desk and intake operations, expansion of cash-based programs, and a return to remote therapeutic monitoring after CMS changes in 2026.
Growth in Large Market Strategic Hospital Alliances: Continued pursuit of large market strategic hospital alliances, with recent wins and ongoing discussions in multiple markets.
De Novo and Acquisition Development: Ongoing development in both PT and injury prevention segments for 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the move for outsourcing of physical therapy services or the general move from medical in-hospital services to out-service facilities driving the motivation from the hospital side?
A:The motivation on the hospital side is multipart. It gives them a broader reach for Metro facilities, with 500,000 to 600,000 visits annually across a 60-facility network. It also enhances patient interaction and care efficacy, benefiting the hospital's musculoskeletal product line. Additional facilities are planned, which will be additive.
Q:Does the $14 million number assume current volumes, and are there other opportunities across the country?
A:The $14 million number assumes current volumes and not additional facilities. Additional facilities are planned, and there are opportunities across the country.
Q:Are there concerns about wage inflationary pressures and a slowdown in PT volumes?
A:The company has a normal inflationary number in the 2026 budget for salaries and does not see high pressure on wages. Mature clinic volumes picked up in Q4 with a 1.5% increase in visits, building momentum for 2026. Initiatives like virtualization of the front desk, AI documentation, and remote therapeutic monitoring are expected to balance costs and revenues.
Q:What is the outlook for non-Medicare pricing and Medicare rate increases?
A:Non-Medicare pricing is expected to achieve a 1.5% to 2% increase. The Medicare rate increase is 1.75% for traditional Medicare visits and some Medicare Advantage visits, resulting in an overall 1.1% increase for all Medicare visits.
Q:What is the payer mix and workers' comp progress?
A:The payer mix in Q4 was 48% commercial, 33% Medicare, and 9.7% workers' comp. Workers' comp visits were consistent with Q3, and all categories increased by 10%-15% year-over-year in Q4 2025.
Q:Why was there a sequential decline in gross margin for injury prevention?
A:The decline was due to staffing up for large contracts before revenue generation and seasonal factors like manufacturing facilities going dark at year-end. However, the company feels positive about the direction and highlighted the strong margin profile of a recent acquisition in New York.
Q:What is the assumption for same-store revenues in the 2026 guidance?
A:Same-store revenues are expected to increase by 2.5% to 3%, driven by visit and rate growth, including Medicare rate increases.
Q:What is the deal contribution in the 2026 guidance?
A:The guidance includes contributions from two acquisitions made this year: one PT group and one IIP group. The IIP business has higher margins than normal.
Q:What are the details of the hospital alliances, including rates, profit headwinds, and exclusivity?
A:The hospital alliances involve hospital outpatient rates, which are better than traditional outpatient rates but vary by market. There are no profit headwinds expected during the setup phase. The relationships are exclusive, with the company being the sole outpatient provider in the hospital networks.
Q:What new service offerings and capabilities does the recent IIP acquisition provide?
A:The acquisition adds testing capabilities, including OSHA and DOT testing, lead exposure testing, drug and alcohol testing, and physicals. It supports infrastructure projects and enhances the company's ability to serve broader patient groups with strong margins.
Q:What is the preference for M&A between PT and IIP segments, and are there larger opportunities in PT?
A:The company is agnostic but prefers IIP due to better organic growth. However, there are fewer IIP deals available. In PT, the company continues to seek opportunities like Metro and smaller clinics, especially in markets with hospital partnerships.
Q:What is the outlook for margins and potential improvement?
A:Margins are expected to improve modestly in 2026 and accelerate in 2027 with hospital agreements. The goal is to return to historical margin levels before Medicare headwinds and other challenges.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on hospital outpatient rates, stating that rates vary by market and instead directed attention to EBITDA contribution in 2027. Additionally, they did not break out deal contributions in the 2026 guidance, suggesting looking at revenue releases for estimates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS pursuit
Chief Officer
City presence
Demand rate
Demand record
IIP income
Medicare chapter
Northwest home
Officer Chief
Officer President
PT income
PT injury
Pacific
USPH
arrangement
calculation
care visit
change
day care
day volume
enterprise
future
hospital affiliation
hundred
improvement
lot excitement
midyear
note
portion
prevention segment
revaluation interest
support
system implementation
visit home
volume clinic
work purpose
world class
USPH Transcript
U.S. Physical Therapy, Inc. (USPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call showed strong financial performance with increased revenues, margins, and EBITDA. The Q&A highlighted positive growth prospects, efficient cost management, and strategic acquisitions. Despite some concerns about wage inflation and unclear details on hospital rates, the company's optimistic guidance, improved margins, and strategic initiatives like AI-driven operations and acquisitions suggest a positive outlook. Given the company's market cap, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
U.S. Physical Therapy, Inc. (USPH) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary and Q&A indicate positive sentiment due to increased EBITDA guidance, strong growth in the injury prevention segment, and favorable financial metrics. The prioritization of acquisitions over buybacks, efficient recruitment strategies, and sustainable growth in key segments further bolster this outlook. While there are some uncertainties, such as the Medicare rate impact, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks, considering the company's small market cap.
U.S. Physical Therapy, Inc. (USPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance, with significant revenue and margin growth, and positive developments in acquisitions and injury prevention. The Q&A indicates solid demand and effective labor management strategies, with AI tools enhancing efficiency. The introduction of a buyback program and slight commercial rate increases further boost sentiment. While there are some uncertainties, such as Medicare rate changes and staffing challenges, the overall outlook is optimistic. Given the company's small-cap status, the positive factors are likely to result in a stock price increase of 2% to 8%.
U.S. Physical Therapy, Inc. (USPH) Q1 2025 Earnings Call Transcript
Unknown5-10
The earnings call reveals a mixed outlook: strong revenue growth from acquisitions and IIP, but declining margins and economic concerns. Q&A insights highlight weather impacts, economic resilience, and lobbying efforts, but lack clarity on inflation adjustments. No share repurchase program or guidance changes were announced. The market cap suggests moderate volatility, but the absence of strong catalysts or negative surprises leads to a neutral prediction.
USPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
